Biodexa Pharmaceuticals (BDRX) Capital Expenditures (2013 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Capital Expenditures of -$38706.6 for Q4 2022, up 5.16% sequentially from -$40812.0 in Q3 2022, and up 84.81% YoY from -$20944.3 in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Capital Expenditures (2013 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Capital Expenditures for 8 years, with the latest figure at -$38706.6 in Q4 2022.
- Quarterly Capital Expenditures rose 84.81% year-over-year to -$38706.6 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was -$596905.2 (up 20.09% YoY) and the FY2025 annual result came in at -$2637.0, up 77.17% from the prior year.
- Capital Expenditures rose to -$38706.6 in Q4 2022 per BDRX's latest filing, from -$40812.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at -$25714.5 in Q4 2019 and troughed at -$262612.6 in Q3 2021.
- A 4-year average of -$121745.1 and a median of -$112076.0 in 2020 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2020 and 2022: Capital Expenditures slumped 357.02% in 2020, then surged 84.81% in 2022.
- Over 4 years, Capital Expenditures stood at -$25714.5 in 2019, then plunged by 357.02% to -$117520.1 in 2020, then plunged by 116.79% to -$254774.0 in 2021, then surged by 84.81% to -$38706.6 in 2022.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$38706.6, -$40812.0, and -$254774.0 for Q4 2022, Q3 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 251.02 Mn |
| 10 | Biodexa Pharmaceuticals | 62,162.53 | -11.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -38,706.63 |
| Dec 31, 2022 | -38,706.63 |
| Sep 14, 2022 | -40,811.96 |
| Sep 14, 2022 | -40,811.96 |
| Dec 31, 2021 | -254,774.00 |
| Dec 31, 2021 | -254,774.00 |
| Sep 17, 2021 | -262,612.65 |
| Sep 17, 2021 | -262,612.65 |
| Dec 31, 2020 | -117,520.14 |
| Dec 31, 2020 | -117,520.14 |
| Sep 10, 2020 | -112,075.95 |
| Sep 10, 2020 | -112,075.95 |
| Dec 31, 2019 | -25,714.50 |
| Dec 31, 2019 | -25,714.50 |
| Dec 31, 2016 | -1.67 Mn |
| Dec 31, 2016 | -1.67 Mn |
| Dec 31, 2015 | -1.40 Mn |
| Dec 31, 2015 | -1.40 Mn |
| Dec 31, 2014 | -1.63 Mn |
| Dec 31, 2014 | -1.63 Mn |